130 related articles for article (PubMed ID: 15707461)
21. Proton pump inhibitors and acute interstitial nephritis.
Geevasinga N; Coleman PL; Webster AC; Roger SD
Clin Gastroenterol Hepatol; 2006 May; 4(5):597-604. PubMed ID: 16630752
[TBL] [Abstract][Full Text] [Related]
22. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Sarela AI; Hick DG; Verbeke CS; Casey JF; Guillou PJ; Clark GW
Arch Surg; 2004 May; 139(5):547-51. PubMed ID: 15136356
[TBL] [Abstract][Full Text] [Related]
23. Lansoprazole overutilization: methods for step-down therapy.
Pohland CJ; Scavnicky SA; Lasky SS; Good CB
Am J Manag Care; 2003 May; 9(5):353-8. PubMed ID: 12744297
[TBL] [Abstract][Full Text] [Related]
24. [Comparative efficacy of proton pump inhibitors in children].
Kornienko EA; Klochko OG
Eksp Klin Gastroenterol; 2003; (6):72-5. PubMed ID: 15065532
[No Abstract] [Full Text] [Related]
25. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
26. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre evaluation.
Enns R; Andrews CN; Fishman M; Hahn M; Atkinson K; Kwan P; Levy A
Can J Gastroenterol; 2004 Sep; 18(9):567-71. PubMed ID: 15457296
[TBL] [Abstract][Full Text] [Related]
27. Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use.
Law JK; Andrews CN; Enns R
Gastrointest Endosc; 2009 Jan; 69(1):3-9. PubMed ID: 18718583
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of use of proton pump inhibitors in Greece.
Ntaios G; Chatzinikolaou A; Kaiafa G; Savopoulos C; Hatzitolios A; Karamitsos D
Eur J Intern Med; 2009 Mar; 20(2):171-3. PubMed ID: 19327607
[TBL] [Abstract][Full Text] [Related]
29. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions.
Kaplan GG; Bates D; McDonald D; Panaccione R; Romagnuolo J
Clin Gastroenterol Hepatol; 2005 Dec; 3(12):1207-14. PubMed ID: 16361046
[TBL] [Abstract][Full Text] [Related]
30. Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Bailie GR; Mason NA; Elder SJ; Andreucci VE; Greenwood RN; Akiba T; Saito A; Bragg-Gresham JL; Gillespie BW; Young EW
Hemodial Int; 2006 Apr; 10(2):180-8. PubMed ID: 16623672
[TBL] [Abstract][Full Text] [Related]
31. Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do.
Doherty GA; Cannon MD; Lynch KM; Ayoubi KZ; Harewood GC; Patchett SE; Murray FE
J Clin Gastroenterol; 2010 Mar; 44(3):e51-6. PubMed ID: 19609216
[TBL] [Abstract][Full Text] [Related]
32. Rational prescribing: practice audit and drug switch in dyspepsia management.
Dott AG; Johnson L
Int J Clin Pract; 1999 Dec; 53(8):599-603. PubMed ID: 10692753
[TBL] [Abstract][Full Text] [Related]
33. Lansoprazole--a new proton pump inhibitor.
Ahmed W; Ali A; Qureshi H; Zuberi SJ; Shamsi ZU
J Pak Med Assoc; 1995 May; 45(5):144-5. PubMed ID: 7563582
[No Abstract] [Full Text] [Related]
34. Inappropriate use of proton pump inhibitors.
Molloy D; Molloy A; O'Loughlin C; Falconer M; Hennessy M
Ir J Med Sci; 2010 Mar; 179(1):73-5. PubMed ID: 19763673
[TBL] [Abstract][Full Text] [Related]
35. Rising rates of proton pump inhibitor prescribing in US emergency departments.
Mazer-Amirshahi M; Mullins PM; van den Anker J; Meltzer A; Pines JM
Am J Emerg Med; 2014 Jun; 32(6):618-22. PubMed ID: 24721025
[TBL] [Abstract][Full Text] [Related]
36. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department.
Bez C; Perrottet N; Zingg T; Leung Ki EL; Demartines N; Pannatier A
J Eval Clin Pract; 2013 Apr; 19(2):374-8. PubMed ID: 22420909
[TBL] [Abstract][Full Text] [Related]
37. [Proton bomb inhibitors: a study of the prescription in a functional recovery unit].
López-Dóriga Bonnardeaux P; Neira Álvarez M; Mansilla Laguía S
Rev Esp Geriatr Gerontol; 2013; 48(6):269-71. PubMed ID: 24099902
[TBL] [Abstract][Full Text] [Related]
38. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients.
Nasser SC; Nassif JG; Dimassi HI
World J Gastroenterol; 2010 Feb; 16(8):982-6. PubMed ID: 20180237
[TBL] [Abstract][Full Text] [Related]
39. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Mabasa VH; Ma J
J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
[TBL] [Abstract][Full Text] [Related]
40. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge.
Leri F; Ayzenberg M; Voyce SJ; Klein A; Hartz L; Smego RA
South Med J; 2013 Apr; 106(4):270-3. PubMed ID: 23558416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
